Cargando…
Protecting blood safety
This chapter is about components of volunteer blood donations that are each transfused as a single unit. A single donation of a pint of whole blood is virtually always separated by centrifugation into a unit of red blood cells and a unit of plasma; a unit of platelets or a unit of cryoprecipitated p...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155561/ http://dx.doi.org/10.1016/B978-012370466-5.50012-1 |
_version_ | 1783522058938875904 |
---|---|
author | Page, Peter L. Pizer, H.F. |
author_facet | Page, Peter L. Pizer, H.F. |
author_sort | Page, Peter L. |
collection | PubMed |
description | This chapter is about components of volunteer blood donations that are each transfused as a single unit. A single donation of a pint of whole blood is virtually always separated by centrifugation into a unit of red blood cells and a unit of plasma; a unit of platelets or a unit of cryoprecipitated plasma can also be prepared, but this is done for less than half of whole blood donations, since patients' clinical needs for platelets and cryoprecipitated plasma are much less than patients' needs for red blood cell transfusion. Each of these units is labeled, and regulated as a drug, following FDA regulations. While today virtually all of these blood components from whole blood donation are from volunteer donors, the FDA would permit paying these donors, but requires that the component's label be marked conspicuously with the words “PAID DONOR” as opposed to “VOLUNTEER DONOR.” Whole blood donation is permitted no more often than once every eight weeks. Most of the plasma separated from red blood cell units is not needed for direct transfusion to patients, and so it is provided as “Recovered Plasma” to large multinational for-profit companies that pool and fractionate it into plasma derivatives. The major source of plasma for plasma derivative manufacture, however, is “Source Plasma” collected by plasmapheresis. |
format | Online Article Text |
id | pubmed-7155561 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
record_format | MEDLINE/PubMed |
spelling | pubmed-71555612020-04-15 Protecting blood safety Page, Peter L. Pizer, H.F. The Social Ecology of Infectious Diseases Article This chapter is about components of volunteer blood donations that are each transfused as a single unit. A single donation of a pint of whole blood is virtually always separated by centrifugation into a unit of red blood cells and a unit of plasma; a unit of platelets or a unit of cryoprecipitated plasma can also be prepared, but this is done for less than half of whole blood donations, since patients' clinical needs for platelets and cryoprecipitated plasma are much less than patients' needs for red blood cell transfusion. Each of these units is labeled, and regulated as a drug, following FDA regulations. While today virtually all of these blood components from whole blood donation are from volunteer donors, the FDA would permit paying these donors, but requires that the component's label be marked conspicuously with the words “PAID DONOR” as opposed to “VOLUNTEER DONOR.” Whole blood donation is permitted no more often than once every eight weeks. Most of the plasma separated from red blood cell units is not needed for direct transfusion to patients, and so it is provided as “Recovered Plasma” to large multinational for-profit companies that pool and fractionate it into plasma derivatives. The major source of plasma for plasma derivative manufacture, however, is “Source Plasma” collected by plasmapheresis. 2008 2008-05-20 /pmc/articles/PMC7155561/ http://dx.doi.org/10.1016/B978-012370466-5.50012-1 Text en Copyright © 2008 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Page, Peter L. Pizer, H.F. Protecting blood safety |
title | Protecting blood safety |
title_full | Protecting blood safety |
title_fullStr | Protecting blood safety |
title_full_unstemmed | Protecting blood safety |
title_short | Protecting blood safety |
title_sort | protecting blood safety |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7155561/ http://dx.doi.org/10.1016/B978-012370466-5.50012-1 |
work_keys_str_mv | AT pagepeterl protectingbloodsafety AT pizerhf protectingbloodsafety |